WO2006042370A1 - Méthodes et préparations pour cheveux et ongles - Google Patents

Méthodes et préparations pour cheveux et ongles Download PDF

Info

Publication number
WO2006042370A1
WO2006042370A1 PCT/AU2005/001628 AU2005001628W WO2006042370A1 WO 2006042370 A1 WO2006042370 A1 WO 2006042370A1 AU 2005001628 W AU2005001628 W AU 2005001628W WO 2006042370 A1 WO2006042370 A1 WO 2006042370A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair
isoflavone
genistein
daidzein
isoflavones
Prior art date
Application number
PCT/AU2005/001628
Other languages
English (en)
Inventor
Alan Husband
Graham Kelly
Original Assignee
Novogen Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004906043A external-priority patent/AU2004906043A0/en
Application filed by Novogen Research Pty Ltd filed Critical Novogen Research Pty Ltd
Publication of WO2006042370A1 publication Critical patent/WO2006042370A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Definitions

  • isoflavones occur principally as glycosides. Following ingestion by man and animals, the glycoside moiety is hydrolysed free by a combination of gastric acid hydrolysis and fermentation by intestinal bacteria. Some of the isoflavones in the aglycone form are absorbed directly and circulate in the blood, while the remainder are metabolised by intestinal fermentation to a variety of compounds which are also absorbed. The absorbed isoflavones and their metabolites appear to undergo little or no further metabolism in the body, being readily transported in the bloodstream, and ultimately being excreted in the urine.
  • compositions comprising phytoestrogen isoflavones, especially when taken orally are effective for improving nail strength by, for example, reducing delamination, splitting and breakage and/or improving nail smoothness and evenness of the nail surface and/or improving hair condition, for example, reducing dryness, split ends, improving lustre, colour and/or body and/or reducing hair loss.
  • the present invention provides a method of maintaining or improving nails and/or hair comprising administering to a subject in need of said improvement an effective amount of a composition comprising an isoflavone, for example, any two or more members of the group consisting of genistein, daidzein, biochanin A, formononetin or the natural glycosides thereof.
  • a composition comprising an isoflavone, for example, any two or more members of the group consisting of genistein, daidzein, biochanin A, formononetin or the natural glycosides thereof.
  • the composition has a higher content of daidzein or daidzein and formononetin than genistein or genistein and biochanin A .
  • the invention also provides the use of an isoflavone or a mixture thereof, for example as described above, for maintaining or improving nails and/or hair.
  • the invention provides a method of treatment comprising administering an effective amount of an isoflavone, particularly a combination of isoflavones as described above or a composition containing same, to a person in need thereof.
  • the invention extends to use of the isoflavones compounds or compositions containing same for the treatment of deficiencies in nail strength and/or hair strength.
  • Certain clovers such as red clover (T. pratense) and subterranean clover (T. subterranean) are the preferred sources. On a dry weight basis, these clovers contain the highest amounts of oestro genie isoflavones of all legumes tested to date with levels of 3-5 g % (T. subterranean) and 1-3 g % (T. pratense). In comparison, soya flour has a level of 0.15-0.30 g %, lentils (0.08-0.12 g %), chick peas (0.07-0.13 g %), and garden peas (0.02-0.03 g %).
  • An additional feature of clovers is that there are wide varieties of cultivars. with widely differing isoflavone levels and ' types. This allows blending of different cultivars to achieve the desired ratio of the different isoflavones, although it is equally possible to use a single cultivar which provides the desired ratio.
  • the oestrogenic isoflavones are restricted principally to the leaf, fruit and root; the stem and petiole contain very little.
  • the leaves are rarely regarded as foodstuff, indeed with these crops, the plants normally are allowed to die and dry out before the seed crop is harvested. Nevertheless, the fresh leaves of these crops could be regarded as a source of phytoestrogens for the invention although the much lower isoflavone content of the leaves of these crops compared to clovers, plus their generally slow growth compared to clovers, suggests that they would not be a preferred source of large-scale isoflavone enrichment.
  • the composition has a higher content of daidzein or daidzein and formononetin than genistein or genistein and biochanin A .
  • the composition has a higher content of biochanin A or formononetin than genistein or daidzein.
  • a typical tablet having an isoflavone content of 40 mg tablet was found to contain an average relative content of about 0.68 genistein, 25.5 biochanin. A, 0.12 daidzein and 13.7 formononetin in a ratio of about 1.89:1 of genistein and biochanin A to daidzein and formononetin.
  • the temperature of the mix can range between ambient temperature and boiling temperature.
  • the exposure time can be between 1 hour and 4 week or even longer. It has been determined that the adequate times for maximal recovery of isoflavones are 2 weeks at 50oC and 24 hours at 90oC.
  • the supernatant is separated from the undissolved plant material and the organic solvent removed by distillation. The aqueous supernatant is then concentrated, by typically by distillation.
  • Additional processing steps can be used, if desired, to convert the extracted natural product to capsule, tablet, or other convenient form for ingestion, using normal techniques for doing this. Otherwise the product can be packaged as a convenient food additive.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention décrit des méthodes de préservation ou d’amélioration des ongles et/ou des cheveux. Lesdites méthodes consistent en l’administration d’une ou de plusieurs isoflavones de type phyto-oestrogènes. La présente invention décrit également l’emploi de l’une ou de plusieurs desdites isoflavones dans la préservation ou l’amélioration de l’aspect et/ou de la résistance des ongles et/ou des cheveux.
PCT/AU2005/001628 2004-10-20 2005-10-20 Méthodes et préparations pour cheveux et ongles WO2006042370A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004906043 2004-10-20
AU2004906043A AU2004906043A0 (en) 2004-10-20 Composition

Publications (1)

Publication Number Publication Date
WO2006042370A1 true WO2006042370A1 (fr) 2006-04-27

Family

ID=36202618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2005/001628 WO2006042370A1 (fr) 2004-10-20 2005-10-20 Méthodes et préparations pour cheveux et ongles

Country Status (1)

Country Link
WO (1) WO2006042370A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120105A3 (fr) * 2007-03-30 2009-02-05 9898 Ltd Technologie de plate-forme pharmaceutique pour le développement de produits naturels
WO2009064245A1 (fr) 2007-11-12 2009-05-22 Mip Technologies Ab Polymères imprimés présentant une affinité pour les protéines et les peptides phosphorylés
KR101393369B1 (ko) * 2012-03-23 2014-05-09 충남대학교산학협력단 고삼의 에틸아세테이트 분획 성분을 유효성분으로 함유하는 모발 성장 촉진용 약학적 조성물
KR20140102558A (ko) * 2013-02-14 2014-08-22 경희대학교 산학협력단 포모노네틴 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 탈모방지 및 발모촉진용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017893A (en) * 1997-08-29 2000-01-25 Natures Sunshine Products, Inc. Use of isoflavones to prevent hair loss and preserve the integrity of existing hair
WO2002011675A2 (fr) * 2000-08-10 2002-02-14 Zelickson M D Brian D Element nutritif organique destine au traitement de la calvitie
WO2002067878A2 (fr) * 2001-02-21 2002-09-06 Skinceuticals, Inc. Utilisations d'extrait de lait de notre-dame dans des compositions pour le soin de la peau
US20030027772A1 (en) * 2001-05-30 2003-02-06 L'oreal Composition containing at least one inhibitor of the enzyme 3-beta-HSD

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017893A (en) * 1997-08-29 2000-01-25 Natures Sunshine Products, Inc. Use of isoflavones to prevent hair loss and preserve the integrity of existing hair
WO2002011675A2 (fr) * 2000-08-10 2002-02-14 Zelickson M D Brian D Element nutritif organique destine au traitement de la calvitie
WO2002067878A2 (fr) * 2001-02-21 2002-09-06 Skinceuticals, Inc. Utilisations d'extrait de lait de notre-dame dans des compositions pour le soin de la peau
US20030027772A1 (en) * 2001-05-30 2003-02-06 L'oreal Composition containing at least one inhibitor of the enzyme 3-beta-HSD

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120105A3 (fr) * 2007-03-30 2009-02-05 9898 Ltd Technologie de plate-forme pharmaceutique pour le développement de produits naturels
CN101790682A (zh) * 2007-03-30 2010-07-28 9898有限公司 发展自然产物的药用平台的技术
AU2008234619B2 (en) * 2007-03-30 2013-04-04 Sinoveda Canada Inc. Pharmaceutical platform technology for the development of natural products
WO2009064245A1 (fr) 2007-11-12 2009-05-22 Mip Technologies Ab Polymères imprimés présentant une affinité pour les protéines et les peptides phosphorylés
KR101393369B1 (ko) * 2012-03-23 2014-05-09 충남대학교산학협력단 고삼의 에틸아세테이트 분획 성분을 유효성분으로 함유하는 모발 성장 촉진용 약학적 조성물
KR20140102558A (ko) * 2013-02-14 2014-08-22 경희대학교 산학협력단 포모노네틴 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 탈모방지 및 발모촉진용 조성물
KR101664531B1 (ko) * 2013-02-14 2016-10-11 경희대학교 산학협력단 포모노네틴 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 탈모방지 및 발모촉진용 조성물

Similar Documents

Publication Publication Date Title
US5830887A (en) Health supplements containing phyto-oestrogens, analogues or metabolites thereof
CA2287965C (fr) Traitement ou prevention des symptomes menopausiques et de l'osteoporose
US6017893A (en) Use of isoflavones to prevent hair loss and preserve the integrity of existing hair
US20020010141A1 (en) Isoflavones for treatment of obesity
US6264997B1 (en) Anti-arteriosclerotic food
US6375994B1 (en) Preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability
WO2006042370A1 (fr) Méthodes et préparations pour cheveux et ongles
CN103702654A (zh) 类胡萝卜素、植物***和维生素c的组合用于预防和/或治疗色素沉着症的用途
KR100419121B1 (ko) 여성 갱년기 증상의 개선 기능을 갖는 생약조성물을함유하는 기능성 식품
AU777632B2 (en) Health supplements containing isoflavones
AU2004224983A1 (en) Health supplements containing isoflavones
US20080161385A1 (en) Composition Inhibiting Sex Hormone-Binding Globulin
Zhao et al. Phytoestrogens and Brain Health
Baker Phytoestrogens for menopausal women
Watanabe et al. Tokyo University of Agriculture, Tokyo, Japan
AU7017198A (en) Treatment or prevention of menopausal symptoms and osteoporosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05821528

Country of ref document: EP

Kind code of ref document: A1